Loading...
Axogen Community
NasdaqCM:AXGN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
Community Investing Ideas
FDA Approval And Improved Coverage Will Unlock Nerve Repair Markets
Key Takeaways Expanding market adoption, payer coverage, and strategic investments position the company for sustained growth, operational leverage, and improved margins. FDA approval for Avance Nerve Graft is set to provide market exclusivity, pricing power, and protection from competition, boosting long-term earnings visibility.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
US$24.71
30.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
16.7% p.a.
Profit Margin
7.96%
Future PE
62.4x
Share price in 2028
US$30.51